CoChat

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Ang, Joo Ern, Gourley, Charlie, Powell, C. Bethan, High, Hilda, Shapira-Frommer, Ronnie, Castonguay, Vincent, De Greve, Jacques, Atkinson, Tina, Yap, Timothy A., Sandhu, Shahneen, Banerjee, Susana, Chen, Lee-May, Friedlander, Michael L., Kaufman, Bella, Oza, Amit M., Matulonis, Ursula, Barber, Louise J., Kozarewa, Iwanka, Fenwick, Kerry, Assiotis, Ioannis, Campbell, James, Chen, Lina, de Bono, Johann S., Gore, Martin E., Lord, Christopher J., Ashworth, Alan, Kaye, Stan B. · 2013 · Clinical Cancer Research
Cited by 139

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: Preclinical data suggest that exposure to PARP inhibitors (PARPi) may compromise benefit to subsequent chemotherapy, particularly platinum-based regimens, in patients with BRCA1/2 mutation carrier ovarian cancer (PBMCOC), possibly through the acquisition of secondary BRCA1/2 mutations. The efficacy of chemotherapy in the PARPi-resistant setting was therefore investigated. Experimental Design: We conducted a retrospective review of PBMCOC who received chemotherapy following disease progression on olaparib, administered at ≥200 mg twice daily for one month or more. Tumor samples were obtained in the post-olaparib setting where feasible and analyzed by massively parallel sequencing. Results: Data were collected from 89 patients who received a median of 3 (range 1–11) lines of pre-olaparib chemotherapy. The overall objective response rate (ORR) to post-olaparib chemotherapy was 36% (24 of 67 patients) by Response Evaluation Criteria in Solid Tumors (RECIST) and 45% (35 of 78) by RECIST and/or Gynecologic Cancer InterGroup (GCIG) CA125 criteria with median progression-free survival (PFS) and overall survival (OS) of 17 weeks [95% confidence interval (CI), 13–21] and 34 weeks (95% CI, 26–42), respectively. For patients receiving platinum-based chemotherapy, ORRs were 40% (19 of 48) and 49% (26/53), respectively, with a median PFS of 22 weeks (95% CI, 15–29) and OS of 45 weeks (95% CI, 15–75). An increased platinum-to-platinum interval was associated with an increased OS and likelihood of response following post-olaparib platinum. No evidence of secondary BRCA1/2 mutation was detected in tumor samples of six PARPi-resistant patients [estimated frequency of such mutations adjusted for sample size: 0.125 (95%-CI: 0–0.375)]. Conclusions: Heavily pretreated PBMCOC who are PARPi-resistant retain the potential to respond to subsequent chemotherapy, including platinum-based agents. These data support the further development of PARPi in PBMCOC. Clin Cancer Res; 19(19); 5485–93. ©2013 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-1262

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 139

Metadata

Authors
Ang, J. E., Gourley, C., Powell, C. B., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T. A., Sandhu, S., Banerjee, S., Chen, L.-M., Friedlander, M. L., Kaufman, B., Oza, A. M., Matulonis, U., Barber, L. J., Kozarewa, I., Fenwick, K., Assiotis, I., Campbell, J., Chen, L., de Bono, J. S., Gore, M. E., Lord, C. J., Ashworth, A., & Kaye, S. B.
Venue
Clinical Cancer Research
Published
2013-10-01
Volume
19
Issue
19
Pages
5485-5493
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2147057518
Cited by
139
References
6
FWCI
7.75
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-1262
The paper
Ang, J. E., Gourley, C., Powell, C. B., High, H., Shapira-Frommer, R., Castonguay, V., De Greve, J., Atkinson, T., Yap, T. A., Sandhu, S., Banerjee, S., Chen, L.-M., Friedlander, M. L., Kaufman, B., Oza, A. M., Matulonis, U., Barber, L. J., Kozarewa, I., Fenwick, K., . . . Kaye, S. B. (2013). Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-1262

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.